About Medasense

Spearheading pain management for improved patient care and reduced healthcare costs

While pain is a major clinical, social and economic problem, affecting quality of life for hundreds of millions of people globally, measurement of pain has remained subjective. Consequently, pain care is not tailored to patients’ specific needs, opioid addiction has become an epidemic, and the direct costs of pain-related healthcare are soaring.

Addressing this problem, Medasense’s NOL® technology is enabling clinicians to personalize pain management, optimize treatment and avoid overmedication with an innovative noninvasive sensor platform and AI technology.

Clear Strategic Path

Medasense’s technology and development strategy address pain management in diverse settings – a $20B market.

A Vision - A Reality

“My vision to help relieve suffering in any care setting is coming to life.”
– Galit Zuckerman-Stark, Founder and CEO

Utilized Worldwide

NOL technology is distributed across Europe by Medtronic, and by other leading partners around the world.

Addressing a global challenge

Latest News

Understand the upswing in new monitoring strategies in anesthesia and the key role of NOL monitoring: “Depth of Anesthesia and Nociception Monitoring: Current State and Vision For 2050” (Anesthesia & Analgesia Feb. 2024)


With over 30 years of experience in healthcare across the Americas, Holly Stewart has joined the Medasense team in the role of North American VP of Sales.


In an update on the U.S. Food and Drug Administration’s efforts in combatting harm from opioids, FDA commissioner Robert M. Califf, MD highlighted the recent marketing authorization of NOL technology


Global Distribution Network

Click on the map to view in full size